What is claimed is:

1. Use of~~A composition comprising~~ a compound of formula I (Compound I)



(I),

or a compound of formula II (Compound II)



(II),

or a pharmaceutically acceptable salt, hydrate, or solvate of Compound I or Compound II, ~~for use~~ in the manufacture of a medicament~~method~~ for treating at least one symptom of an anxiety disorder in a human subject who is diagnosed with Major Depressive D~~the anxiety d~~isorder (MDD), wherein the medicament is to be~~method comprises~~ orally administered~~ing~~ to the subject, wherein the medicament comprises a therapeutically effective amount of the composition, and wherein the therapeutically effective amount is a total daily dose of Compound I or Compound II ~~selected from the group consisting~~ of~~:~~

~~(i) about 0.1 mg to less than 3.0 mg;~~

~~(ii) about 0.2 mg to about 2.9 mg;~~

~~(iii) about 0.3 mg to about 2.8 mg;~~

~~(iv) about 0.4 mg to about 2.7 mg;~~

~~(v) about~~ 0.5 mg to ~~about 2.6 mg;~~

~~(vi) about 0.6 mg to about~~ 2.5 mg~~,~~

~~(vii) about 0.4 mg to about 0.6 mg; and~~

~~(viii) about 0.5 mg~~.

2. The use according to~~composition of~~ claim 1, wherein the therapeutically effective amount is a total daily dose of ~~Compound I or Compound II selected from the group consisting of:~~

~~(i) about 0.25 mg to about 2.5 mg;~~

~~(ii) about 0.25 mg to about 1.5 mg;~~

~~(iii) about 0.25 to about 1.0 mg;~~

~~(iv) about 0.25 mg to about 0.75 mg;~~

~~(v) about 0.1 mg to about 2.0 mg;~~

~~(vi) about 0.1 mg to about 1.0 mg; and~~

~~(vii) about 0.1 mg to about 0.5 mg.~~

~~3. The composition of claim 1 or 2, which comprises about~~ 0.5 mg of Compound I or Compound II.

~~4. The composition of any one of claims 1 to 3, wherein the composition comprises (2S)-1-[4-(3,4-dichlorophenyl)piperidin-1-yl]-3-[2-(5-methyl-1,3,4-oxadiazol-2-yl)benzo[*b*]furan-4-yloxy]propan-2-ol monohydrochloride or (2*S*)-1-[4-(3,4-dichlorophenyl)piperidin-1-yl]-3-[2-(5-hydroxymethyl-1,3,4-oxadiazol-2-yl)benzo[*b*]furan-4-yloxy]propan-2-ol monohydrochloride.~~

~~5. The composition of any one of claims 1 to 3, wherein the composition comprises 0.5 mg of (2S)-1-[4-(3,4-dichlorophenyl)piperidin-1-yl]-3-[2-(5-methyl-1,3,4-oxadiazol-2-yl)benzo[*b*]furan-4-yloxy]propan-2-ol monohydrochloride.~~

6. The composition of any one of claims 1 to 5, wherein the subject has been diagnosed with a co-morbid mental disorder.

7. The composition of any one of claims 1 to 6, wherein the subject has not been diagnosed with a co-morbid mental disorder.

8. The composition of any one of claims 1 to 7, wherein the anxiety disorder is selected from the group consisting of: Separation Anxiety Disorder, Selective Mutism, Specific Phobia, Social Anxiety Disorder (Social Phobia), Panic Disorder, Panic Attack Specifier, Agoraphobia, Generalized Anxiety Disorder, Substance/Medication-Induced Anxiety Disorder, Anxiety Disorder Due to Another Medical Condition, Other Specified Anxiety Disorder, Unspecified Anxiety Disorder, Obsessive-Compulsive Disorder, Body Dysmorphic Disorder, Hoarding Disorder, Trichotillomania (Hair-Pulling Disorder), Excoriation (Skin-Picking) Disorder, Substance/Medication-Induced Obsessive-Compulsive and Related Disorder, Obsessive-Compulsive and Related Disorder Due to Another Medical Condition, Other Specified Obsessive-Compulsive and Related Disorder, Unspecified Obsessive-Compulsive and Related Disorder, Reactive Attachment Disorder, Disinhibited Social Engagement Disorder, Posttraumatic Stress Disorder, Acute Stress Disorder, Adjustment Disorders, Other Specified Trauma- and Stressor-Related Disorder, Unspecified Trauma- and Stressor-Related Disorder.

9. A method of treating at least one symptom of an anxiety disorder in a human subject who is diagnosed with the anxiety disorder, wherein the method comprises orally administering to the subject a therapeutically effective amount of a compound of formula I (Compound I),



(I),

or a compound of formula II (Compound II)



(II),

or a pharmaceutically acceptable salt, hydrate, or solvate of Compound I or II, wherein the therapeutically effective amount is a total daily dose of Compound I or Compound II selected from the group consisting of:

(i) about 0.1 mg to less than 3.0 mg;

(ii) about 0.2 mg to about 2.9 mg;

(iii) about 0.3 mg to about 2.8 mg;

(iv) about 0.4 mg to about 2.7 mg;

(v) about 0.5 mg to about 2.6 mg;

(vi) about 0.6 mg to about 2.5 mg,

(vii) about 0.4 mg to about 0.6 mg; and

(viii) about 0.5 mg.

~~10. The method of claim 9, wherein the therapeutically effective amount is a total daily dose of Compound I or Compound II selected from the group consisting of:~~

~~(i) about 0.25 mg to about 2.5 mg;~~

~~(ii) about 0.25 mg to about 1.5 mg;~~

~~(iii) about 0.25 to about 1.0 mg;~~

~~(iv) about 0.25 mg to about 0.75 mg;~~

~~(v) about 0.1 mg to about 1.0 mg;~~

~~(vi) about 0.1 mg to about 0.75 mg; and~~

~~(vii) about 0.1 mg to about 0.5 mg.~~

~~11. The method of claim 9 or 10, wherein the therapeutically effective amount is a total daily dose of about 0.5 mg Compound I or Compound II.~~

3~~12~~. The use according to~~method of any one of~~ claim~~s~~ 1~~9~~ or~~to~~ 2~~11~~, wherein the human subject has been diagnosed with moderate to severe M~~ajor D~~epressive ~~D~~isorder.

~~13. The method of any one of claims 9 to 12, wherein the anxiety disorder is selected from the group consisting of: Separation Anxiety Disorder, Selective Mutism, Specific Phobia, Social Anxiety Disorder (Social Phobia), Panic Disorder, Panic Attack Specifier, Agoraphobia, Generalized Anxiety Disorder, Substance/Medication-Induced Anxiety Disorder, Anxiety Disorder Due to Another Medical Condition, Other Specified Anxiety Disorder, Unspecified Anxiety Disorder, Obsessive-Compulsive Disorder, Body Dysmorphic Disorder, Hoarding Disorder, Trichotillomania (Hair-Pulling Disorder), Excoriation (Skin-Picking) Disorder, Substance/Medication-Induced Obsessive-Compulsive and Related Disorder, Obsessive-Compulsive and Related Disorder Due to Another Medical Condition, Other Specified Obsessive-Compulsive and Related Disorder, Unspecified Obsessive-Compulsive and Related Disorder, Reactive Attachment Disorder, Disinhibited Social Engagement Disorder, Posttraumatic Stress Disorder, Acute Stress Disorder, Adjustment Disorders, Other Specified Trauma- and Stressor-Related Disorder, Unspecified Trauma- and Stressor-Related Disorder.~~

414. The use according tomethod of any one of claims 19 to 313, wherein Compound I or Compound II is to be administered for a first treatment period selected from the group consisting of at least 1 week, at least 2 weeks, at least 3 weeks, at least 4 weeks, at least 5 weeks and at least 6 weeks and, if the first treatment period results in reduction of the at least one anxiety symptom in the subject, then the treating is continued for a second treatment period selected from the group consisting of at least 12 weeks, at least 24 weeks, and at least 48 weeks.

15. A method of treating at least one symptom of an anxiety disorder in a human subject who is diagnosed with the anxiety disorder, wherein the method comprises orally administering to the subject a therapeutically effective amount of (2S)-1-[4-(3,4-dichlorophenyl)piperidin-1-yl]-3-[2-(5-methyl-1,3,4-oxadiazol-2-yl)benzo[*b*]furan-4-yloxy]propan-2-ol monohydrochloride, wherein the therapeutically effective amount is a total daily dose of between 0.5 mg to 2.5 mg of Compound I.

16. A composition comprising (2S)-1-[4-(3,4-dichlorophenyl)piperidin-1-yl]-3-[2-(5-methyl-1,3,4-oxadiazol-2-yl)benzo[*b*]furan-4-yloxy]propan-2-ol monohydrochloride for use in a method for treating at least one symptom of an anxiety disorder in a human subject who is diagnosed with the anxiety disorder, wherein the method comprises orally administering to the subject a therapeutically effective amount of the composition, wherein the therapeutically effective amount is a total daily dose of between 0.5 mg to 2.5 mg of Compound I.